562 related articles for article (PubMed ID: 18759700)
1. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
Taplin ME
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
[TBL] [Abstract][Full Text] [Related]
2. Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
Taplin ME
Nat Clin Pract Oncol; 2007 Apr; 4(4):236-44. PubMed ID: 17392714
[TBL] [Abstract][Full Text] [Related]
3. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.
Taplin ME; Balk SP
J Cell Biochem; 2004 Feb; 91(3):483-90. PubMed ID: 14755679
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.
Shiota M; Yokomizo A; Naito S
Free Radic Biol Med; 2011 Oct; 51(7):1320-8. PubMed ID: 21820046
[TBL] [Abstract][Full Text] [Related]
6. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N
Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
[TBL] [Abstract][Full Text] [Related]
7. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
Locke JA; Guns ES; Lubik AA; Adomat HH; Hendy SC; Wood CA; Ettinger SL; Gleave ME; Nelson CC
Cancer Res; 2008 Aug; 68(15):6407-15. PubMed ID: 18676866
[TBL] [Abstract][Full Text] [Related]
8. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.
Niu Y; Chang TM; Yeh S; Ma WL; Wang YZ; Chang C
Oncogene; 2010 Jun; 29(25):3593-604. PubMed ID: 20440270
[TBL] [Abstract][Full Text] [Related]
9. Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer.
Wang G; Sadar MD
J Cell Biochem; 2006 May; 98(1):36-53. PubMed ID: 16440300
[TBL] [Abstract][Full Text] [Related]
10. Castration-resistant prostate cancer: locking up the molecular escape routes.
Attar RM; Takimoto CH; Gottardis MM
Clin Cancer Res; 2009 May; 15(10):3251-5. PubMed ID: 19447877
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial androgen receptor targeted therapy for prostate cancer.
Singh P; Uzgare A; Litvinov I; Denmeade SR; Isaacs JT
Endocr Relat Cancer; 2006 Sep; 13(3):653-66. PubMed ID: 16954423
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
Singer EA; Golijanin DJ; Messing EM
Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
[TBL] [Abstract][Full Text] [Related]
13. Novel secondary hormonal therapy in advanced prostate cancer: an update.
Van Allen EM; Ryan CJ
Curr Opin Urol; 2009 May; 19(3):315-21. PubMed ID: 19342958
[TBL] [Abstract][Full Text] [Related]
14. Novel concepts in androgen receptor blockade.
Hsieh AC; Ryan CJ
Cancer J; 2008; 14(1):11-4. PubMed ID: 18303477
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens.
Whitaker HC; Hanrahan S; Totty N; Gamble SC; Waxman J; Cato AC; Hurst HC; Bevan CL
Clin Cancer Res; 2004 Nov; 10(21):7392-401. PubMed ID: 15534116
[TBL] [Abstract][Full Text] [Related]
16. Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation.
Nelson EC; Cambio AJ; Yang JC; Lara PN; Evans CP
Nat Clin Pract Urol; 2007 Feb; 4(2):82-94. PubMed ID: 17287869
[TBL] [Abstract][Full Text] [Related]
17. Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance.
Locke JA; Guns ES; Lehman ML; Ettinger S; Zoubeidi A; Lubik A; Margiotti K; Fazli L; Adomat H; Wasan KM; Gleave ME; Nelson CC
Prostate; 2010 Feb; 70(3):239-51. PubMed ID: 19790237
[TBL] [Abstract][Full Text] [Related]
18. Targeting the androgen receptor in hormone-refractory prostate cancer--new concepts.
Eder IE; Haag P; Bartsch G; Klocker H
Future Oncol; 2005 Feb; 1(1):93-101. PubMed ID: 16555979
[TBL] [Abstract][Full Text] [Related]
19. Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.
Nishiyama T; Suzuki K; Yamana K; Tonegawa E; Wako K; Takahashi K
Expert Rev Anticancer Ther; 2006 Feb; 6(2):259-68. PubMed ID: 16445378
[TBL] [Abstract][Full Text] [Related]
20. Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer.
Griffiths K; Morton MS; Nicholson RI
Eur Urol; 1997; 32 Suppl 3():24-40. PubMed ID: 9267783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
